Full View

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

S Verma, SH Li, MV Badiwala, RD Weisel… - Circulation, 2002 - Am Heart Assoc
Background—C-reactive protein (CRP) has been suggested to actively participate in the
development of atherosclerosis. In the present study, we examined the role of the potent …
被引用次数：1274 相关文章

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

S Verma, SH Li, MV Badiwala, RD Weisel… - …, 2002 - pubmed.ncbi.nlm.nih.gov
Background C-reactive protein (CRP) has been suggested to actively participate in the
development of atherosclerosis. In the present study, we examined the role of the potent …

Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein

S Verma, SH Li, MV Badiwala, RD Weisel, PWM Fedak… - Circulation, 2002 - cir.nii.ac.jp
抄録< jats: p>< jats: bold>< jats: italic>< jats: bold>< jats: italic> Background</jats:
italic></jats: bold>—</jats: italic></jats: bold> C-reactive protein (CRP) has been suggested …
[PDF] renkelilab.com

[PDF][PDF] Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein

S Verma, SH Li, MV Badiwala, RD Weisel, PWM Fedak… - 2002 - renkelilab.com
Background—C-reactive protein (CRP) has been suggested to actively participate in the
development of atherosclerosis. In the present study, we examined the role of the potent …
[PDF] academia.edu

[PDF][PDF] Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein

S Verma, SH Li, MV Badiwala, RD Weisel, PWM Fedak… - 2002 - academia.edu
Background—C-reactive protein (CRP) has been suggested to actively participate in the
development of atherosclerosis. In the present study, we examined the role of the potent …

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein.

S Verma, SH Li, MV Badiwala, RD Weisel, PW Fedak… - Circulation, 2002 - europepmc.org
Background C-reactive protein (CRP) has been suggested to actively participate in the
development of atherosclerosis. In the present study, we examined the role of the potent …

[引用][C] Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

S VERMA, SH LI, MV BADIWALA… - … (New York, NY), 2002 - pascal-francis.inist.fr
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive
protein CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
[PDF] psu.edu

[PDF][PDF] Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein

S Verma, SH Li, MV Badiwala, RD Weisel, PWM Fedak… - 2002 - Citeseer
Background—C-reactive protein (CRP) has been suggested to actively participate in the
development of atherosclerosis. In the present study, we examined the role of the potent …

[引用][C] Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

S VERMA - Circulation, 2002 - cir.nii.ac.jp
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive
protein | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

[引用][C] Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

S VERMA, SH LI, MV BADIWALA… - …, 2002 - Lippincott Williams & Wilkins